(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of 2.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Kymera Therapeutics's revenue in 2026 is $43,734,000.On average, 25 Wall Street analysts forecast KYMR's revenue for 2026 to be $3,581,550,615, with the lowest KYMR revenue forecast at $705,100,465, and the highest KYMR revenue forecast at $7,554,647,835. On average, 21 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,875,894,084, with the lowest KYMR revenue forecast at -$916,630,604, and the highest KYMR revenue forecast at $7,361,824,443.
In 2028, KYMR is forecast to generate $3,166,116,933 in revenue, with the lowest revenue forecast at -$1,762,751,162 and the highest revenue forecast at $7,554,647,835.